Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ixazomib - Takeda Oncology

Drug Profile

Ixazomib - Takeda Oncology

Alternative Names: Ixazomib citrate; MLN-2238; MLN-9708; NINLARO

Latest Information Update: 04 Dec 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Millennium Pharmaceuticals; University of California, San Diego
  • Developer Celgene Corporation; Helsinki University Central Hospital; HOVON Foundation; Massachusetts General Hospital; National Cancer Institute (USA); Northside Hospital; Northwestern University; Takeda Oncology; University of Texas M. D. Anderson Cancer Center
  • Class Antineoplastics; Antivirals; Organic boron compounds; Small molecules
  • Mechanism of Action Apoptosis stimulants; Proteasome inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Multiple myeloma; Amyloidosis
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Multiple myeloma
  • Phase III Amyloid light-chain amyloidosis
  • Phase II Acute myeloid leukaemia; Amyloidosis; Follicular lymphoma; Haematological malignancies; Lymphoma; Mantle-cell lymphoma; Myelodysplastic syndromes; Waldenstrom's macroglobulinaemia
  • Phase I/II Bladder cancer; Graft-versus-host disease; HIV infections
  • Phase I Non-small cell lung cancer; Pancreatic cancer; Precursor cell lymphoblastic leukaemia-lymphoma
  • No development reported Lupus nephritis
  • Discontinued Solid tumours

Most Recent Events

  • 20 Nov 2019 Celgene Corporation has been acquired by Bristol-Myers Squibb
  • 01 Nov 2019 Millennium Pharmaceuticals and Massachusetts General Hospital completes a phase-I trial in Precursor-cell-lymphoblastic-leukaemia-lymphoma in USA (PO) (NCT02228772)
  • 20 Sep 2019 Phase-I/II clinical trials in Acute myeloid leukaemia (Combination therapy, Second-line therapy or greater) in USA (PO) (NCT04079738)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top